SEC Company Response from RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) (RLMD) — Aug 19, 2020
RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
Date: Aug. 19, 2020 · CIK: 0001553643 · Accession: 0001213900-20-022900
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-245054
Letter
RELMADA THERAPEUTICS, INC.
880 Third Avenue, 12th Floor
New York, New York 10022
August 19, 2020
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attention: Ms. Deanna Virginio
Re: Relmada Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-245054
Ladies and Gentlemen:
Relmada Therapeutics, Inc. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern time, Friday, August 21, 2020, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Very truly yours,
RELMADA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
RELMADA THERAPEUTICS, INC.
880 Third Avenue, 12th Floor
New York, New York 10022
August 19, 2020
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attention: Ms. Deanna Virginio
Re:
Relmada Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-245054
Ladies and Gentlemen:
Relmada Therapeutics, Inc. (the
“Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended,
acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will
become effective as of 4:00 p.m. Eastern time, Friday, August 21, 2020, or as soon thereafter as practicable, or at such
later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation
Finance of the Securities and Exchange Commission.
Very truly yours,
RELMADA THERAPEUTICS, INC.
By:
/s/ Sergio Traversa
Name: Sergio Traversa
Title: Chief Executive Officer